Antihistone and other autoantibodies in β-thalassemia major patients receiving iron chelators

Acta Haematologica

Volumn 109, Issue 1, 2003, Pages 35-39

  Pradhan, Vandana ^a   Badakere, Suresh ^a   Ghosh, Kanjaksha ^a  

^a KEM HOSPITAL   (India)

Author keywords

Thalassemia; Antihistone antibodies; Autoantibodies; Deferiprone(l1); Desferrioxamine

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; DEFERIPRONE; DEFEROXAMINE; HISTONE H1; HISTONE H2A; HISTONE H3; HISTONE H4; IMMUNOGLOBULIN G; IRON CHELATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RHEUMATOID FACTOR; HISTONE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNITY; BETA THALASSEMIA; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANTIBODY PRODUCTION; BLOOD; CLASSIFICATION; COMPARATIVE STUDY; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTIBODY FORMATION; AUTOANTIBODIES; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; DRUG EVALUATION; FEMALE; HISTONES; HUMANS; IMMUNOGLOBULIN G; IRON CHELATING AGENTS; MALE; PYRIDONES;

EID: 0037209136     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067277     Document Type: Article

References (27)

1. Tan EM: Autoantibodies to nuclear antigens (ANA): Their immunobiology and medicine. Adv Immunol 1982;33:167.
2. Roitt I: Essential Immunology, ed 8. Oxford, Blackwell Scientific Publications, 1994.
3. Berdukas V: Anti-nuclear antibodies in patients taking L1. Lancet 1991;323:672.
4. Agarwal M: Oral iron chelation: A review with special emphasis on Indian work on deferiprone (L1). Indian J Pediatr 1993;60:509.
5. Agarwal M, Vishwanathan C, Gupte S, Desai N, Vasandani D, Bhave A: Anti-nuclear antibody positivity in multitransfused thalassemia major. Indian J Pediatr 1997;29:607.
6. Bartlett A, Hoffbrand A, Kontoghiorghes G: Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxyprid-4-one (L1). Br J Haematol 1990;76:301.
7. Olivieri N, Brittenham G, Matsui D, Cameron R, Templeton D, Koren G: Iron chelation therapy with oral iron chelator deferiprone in patients with thalassemia major. N Engl J Med 1995;332:918.
8. Olivieri N: Long-term therapy with deferiprone. Acta Haematol 1996;95:37.
9. Agarwal M, Gupte S, Vasandani D, Vishwanathan C, Puniyani R, Bhave A: Efficacy and safety of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of β-thalassemia major with iron overload. J Assoc Physicians India 1991;39:669.
10. Agarwal M, Gupte S, Vishwanathan C: Long-term assessment of efficacy and safety on L1, an oral iron chelator in transfusion-dependent thalassemia: An Indian trial. Br J Haematol 1992;82:460.
11. Al Rafaie F, Hershko C, Hoffbrand AV: Results of long-term deferiprone (L1) therapy: A report by the international study group on oral iron chelator. Br J Haematol 1995;91:224.
12. Krippner H, Springer B, Merle S, Pirle K: Anti-bodies to histone of the IgG and IgM class in systemic lupus erythematosus. Clin Exp Immunol 1984;58:49.
13. Badakere SS, Chablani A, Bhatia H, Panjwani D, Mehta B: Anti-nuclear factor in some autoimmune disorders. Proc Recent Trends Immunohaematol. Bombay, Indian Council of Medical Research, 1982, p 101.
14. Badakere S, Chablani A: Immunofluorescent techniques in immunohaematology. Immunohaematol Bull 1985;16:1.
15. Badakere S, Chablani A, Bhatia H: Anti-nuclear antibody negative systemic lupus erythematosus in India with anti-ssDNA antibodies. Br J Rheumatol 1987;26:476.
16. Badakere S, Chablani A, Bhatia H: Chromic chloride as a coupling agent in anti-dsDNA passive haemagglutination test. A preliminary report. Indian J Med Res 1984;79:448.
17. Badakere S, Chablani A: Significance of antibodies to ENA (Sm + RNP) and patterns of immunofluorescence in the diagnosis of some collagen vascular autoimmune disorders. Indian J Haematol Blood Transfus 1994;12:107.
18. Chablani A, Badakere S, Bhatia H: Further studies on ds-DNA antibodies by passive haemagglutination technique. Indian J Haematol 1985;3:16.
19. Gripenberg M, Wafin F, Isomaki H, Linder E: A simple enzyme immunoassay for the demonstration of rheumatoid factor. J Immunol Methods 1979;31:109.
20. Kurki P, Gripenberg M, Partanen P, Heive T: Screening test for rheumatoid factor and antibodies to DNA and extractable nuclear antigens. J Clin Pathol 1987;40:1475.
21. Fishbein A, Alarcon-Sergovi D, Vega J: Antibodies to histones in systemic lupus erythematosus. Clin Exp Immunol 1997;36:145.
22. Mehta J, Singhal S, Mehta B: Oral iron chelator L1 and autoimmunity. Lancet 1993;81:1971.
23. Berkovitch M, Laxes R, Inmas R: Arthropathy in thalassemia patients receiving deferiprone. Lancet 1994;343:1471.
24. Al Rafaie F, Wonke B, Hoffbrand AV: Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 1992;90: 593.
25. Al Rafaie F, Hoffbrand AV, Norley P, Wonke B, Wickens DG: Letter to the editor. Blood 1993;81:1971.
26. Goiud M, Aitkaci M, Monier J: Histone antibodies in systemic lupus erythematosus. Arthritis Rheum 1982;25:407.
27. Fellows G, Gittoes M, Woppeck J, Wainwright A, Turner B: Individual variation in the isotype profile of anti-histone autoantibodies in systemic lupus erythematosus. Clin Exp Immunol 1988;72:440.